Parabilis Medicines, Inc. (NASDAQ:PBLS) Stock Has Average Target Price of $41.67

Shares of Parabilis Medicines, Inc. (NASDAQ:PBLS) have earned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $41.67.

Several research analysts have recently issued reports on PBLS shares. Weiss Ratings lowered shares of Parabilis Medicines from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, October 2nd. Zacks Research upgraded shares of Parabilis Medicines to a “hold” rating in a research report on Tuesday, July 7th. Evercore initiated coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They set an “outperform” rating for the company. Lifesci Capital raised shares of Parabilis Medicines to a “strong-buy” rating in a research note on Monday, July 6th. Finally, Leerink Partners initiated coverage on shares of Parabilis Medicines in a report on Monday, July 6th. They issued an “outperform” rating and a $40.00 price objective on the stock.

Institutional Trading of Parabilis Medicines

A number of institutional investors have recently bought and sold shares of PBLS. ARCH Venture Management LLC acquired a new stake in Parabilis Medicines during the 2nd quarter worth $175,517,789. venBio Partners LLC bought a new stake in shares of Parabilis Medicines during the 2nd quarter valued at $144,149,497. Alphabet Inc. acquired a new position in shares of Parabilis Medicines in the 2nd quarter valued at $134,647,000. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Parabilis Medicines in the 2nd quarter valued at $114,042,000. Finally, Jupiter Topco LLC acquired a new position in shares of Parabilis Medicines in the 2nd quarter valued at $62,710,000.

Parabilis Medicines Stock Performance

Parabilis Medicines stock opened at $22.75 on Thursday. The firm has a 50-day moving average price of $35.19. The company has a market capitalization of $2.81 billion and a PE ratio of -10.68. Parabilis Medicines has a 12-month low of $22.66 and a 12-month high of $42.49.

Parabilis Medicines (NASDAQ:PBLS) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The business had revenue of $0.15 million during the quarter. Research analysts predict that Parabilis Medicines will post -3.09 earnings per share for the current fiscal year.

About Parabilis Medicines